MedMira Inc. (MMIRF)
USD 0.02
(-70.43%)
USD 0.02
(-70.43%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -2.67 Million CAD | -46.09% |
| 2022 | -1.83 Million CAD | -171.02% |
| 2021 | -675.79 Thousand CAD | 66.96% |
| 2020 | -2.04 Million CAD | 2.9% |
| 2019 | -2.1 Million CAD | 16.06% |
| 2018 | -2.5 Million CAD | 5.7% |
| 2017 | -2.66 Million CAD | 48.41% |
| 2016 | -5.15 Million CAD | -59.72% |
| 2015 | -3.22 Million CAD | 15.79% |
| 2014 | -3.83 Million CAD | -853.35% |
| 2013 | -402.3 Thousand CAD | -111.93% |
| 2012 | 3.37 Million CAD | 168.93% |
| 2011 | -4.89 Million CAD | -10.72% |
| 2010 | -4.41 Million CAD | 16.05% |
| 2009 | -5.26 Million CAD | 25.01% |
| 2008 | -7.01 Million CAD | -11.62% |
| 2007 | -6.28 Million CAD | 13.72% |
| 2006 | -7.28 Million CAD | -19.34% |
| 2005 | -6.1 Million CAD | -52.94% |
| 2004 | -3.99 Million CAD | 13.5% |
| 2003 | -4.61 Million CAD | 18.42% |
| 2002 | -5.65 Million CAD | 21.38% |
| 2001 | -7.19 Million CAD | -148.39% |
| 2000 | -2.89 Million CAD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q3 | -780.14 Thousand CAD | -32.05% |
| 2024 Q2 | -590.78 Thousand CAD | 24.29% |
| 2024 Q1 | -780.36 Thousand CAD | 18.94% |
| 2023 Q1 | -632.44 Thousand CAD | -36.55% |
| 2023 FY | -2.67 Million CAD | -46.09% |
| 2023 Q2 | -490.5 Thousand CAD | 22.44% |
| 2023 Q3 | -589.98 Thousand CAD | -20.28% |
| 2023 Q4 | -962.71 Thousand CAD | -63.18% |
| 2022 Q4 | -463.15 Thousand CAD | -12.67% |
| 2022 Q3 | -411.06 Thousand CAD | 12.23% |
| 2022 FY | -1.83 Million CAD | -171.02% |
| 2022 Q1 | -489 Thousand CAD | 23.23% |
| 2022 Q2 | -468.34 Thousand CAD | 4.23% |
| 2021 Q3 | -338.05 Thousand CAD | 18.72% |
| 2021 Q1 | 715.17 Thousand CAD | 364.95% |
| 2021 Q2 | -415.93 Thousand CAD | -158.16% |
| 2021 FY | -675.79 Thousand CAD | 66.96% |
| 2021 Q4 | -636.98 Thousand CAD | -88.43% |
| 2020 Q1 | -468.67 Thousand CAD | -4.49% |
| 2020 Q3 | -692.47 Thousand CAD | -12.73% |
| 2020 Q2 | -614.3 Thousand CAD | -31.07% |
| 2020 FY | -2.04 Million CAD | 2.9% |
| 2020 Q4 | -269.92 Thousand CAD | 61.02% |
| 2019 FY | -2.1 Million CAD | 16.06% |
| 2019 Q1 | -550.03 Thousand CAD | -9.43% |
| 2019 Q2 | -595.32 Thousand CAD | -8.23% |
| 2019 Q3 | -512.55 Thousand CAD | 13.9% |
| 2019 Q4 | -448.53 Thousand CAD | 12.49% |
| 2018 Q1 | -636.17 Thousand CAD | -14.03% |
| 2018 FY | -2.5 Million CAD | 5.7% |
| 2018 Q4 | -502.66 Thousand CAD | 23.47% |
| 2018 Q3 | -656.77 Thousand CAD | 8.0% |
| 2018 Q2 | -713.85 Thousand CAD | -12.21% |
| 2017 Q2 | -549.6 Thousand CAD | 31.45% |
| 2017 FY | -2.66 Million CAD | 48.41% |
| 2017 Q4 | -557.88 Thousand CAD | 25.79% |
| 2017 Q3 | -751.76 Thousand CAD | -36.78% |
| 2017 Q1 | -801.8 Thousand CAD | 61.11% |
| 2016 Q1 | -900.41 Thousand CAD | -201.84% |
| 2016 FY | -5.15 Million CAD | -59.72% |
| 2016 Q2 | -981.73 Thousand CAD | -9.03% |
| 2016 Q3 | -1.21 Million CAD | -23.68% |
| 2016 Q4 | -2.06 Million CAD | -69.82% |
| 2015 Q4 | -298.31 Thousand CAD | 64.99% |
| 2015 Q3 | -852.04 Thousand CAD | 17.81% |
| 2015 FY | -3.22 Million CAD | 15.79% |
| 2015 Q2 | -1.03 Million CAD | 0.56% |
| 2015 Q1 | -1.04 Million CAD | -189.03% |
| 2014 Q4 | -360.69 Thousand CAD | 70.39% |
| 2014 FY | -3.83 Million CAD | -853.35% |
| 2014 Q3 | -1.21 Million CAD | 14.07% |
| 2014 Q1 | -839.35 Thousand CAD | -10.63% |
| 2014 Q2 | -1.41 Million CAD | -68.86% |
| 2013 Q4 | -758.7 Thousand CAD | 11.75% |
| 2013 Q2 | 1.07 Million CAD | 654.28% |
| 2013 Q1 | 142.35 Thousand CAD | -98.26% |
| 2013 Q3 | -859.68 Thousand CAD | -180.06% |
| 2013 FY | -402.3 Thousand CAD | -111.93% |
| 2012 FY | 3.37 Million CAD | 168.93% |
| 2012 Q1 | -1.84 Million CAD | -15.82% |
| 2012 Q2 | -2.41 Million CAD | -30.79% |
| 2012 Q4 | 8.16 Million CAD | 607.34% |
| 2012 Q3 | -1.6 Million CAD | 33.37% |
| 2011 Q4 | -1.59 Million CAD | -80.97% |
| 2011 FY | -4.89 Million CAD | -10.72% |
| 2011 Q2 | -1.3 Million CAD | -17.36% |
| 2011 Q1 | -1.11 Million CAD | 37.03% |
| 2011 Q3 | -881.32 Thousand CAD | 32.44% |
| 2010 FY | -4.41 Million CAD | 16.05% |
| 2010 Q4 | -1.76 Million CAD | -182.91% |
| 2010 Q3 | -623.89 Thousand CAD | 34.79% |
| 2010 Q2 | -956.68 Thousand CAD | 10.84% |
| 2010 Q1 | -1.07 Million CAD | 20.02% |
| 2009 Q3 | -976.93 Thousand CAD | 18.3% |
| 2009 Q2 | -1.19 Million CAD | 31.63% |
| 2009 Q1 | -1.74 Million CAD | 50.51% |
| 2009 FY | -5.26 Million CAD | 25.01% |
| 2009 Q4 | -1.34 Million CAD | -37.33% |
| 2008 Q1 | -1.47 Million CAD | 30.82% |
| 2008 FY | -7.01 Million CAD | -11.62% |
| 2008 Q4 | -3.53 Million CAD | -156.57% |
| 2008 Q3 | -1.37 Million CAD | -117.7% |
| 2008 Q2 | -632.63 Thousand CAD | 57.1% |
| 2007 Q4 | -2.13 Million CAD | -82.78% |
| 2007 Q2 | -1.51 Million CAD | -2.27% |
| 2007 FY | -6.28 Million CAD | 13.72% |
| 2007 Q3 | -1.16 Million CAD | 22.86% |
| 2007 Q1 | -1.47 Million CAD | 31.57% |
| 2006 Q3 | -2.2 Million CAD | -88.71% |
| 2006 Q4 | -2.16 Million CAD | 2.02% |
| 2006 FY | -7.28 Million CAD | -19.34% |
| 2006 Q1 | -1.75 Million CAD | 21.26% |
| 2006 Q2 | -1.16 Million CAD | 33.44% |
| 2005 Q1 | -1.17 Million CAD | -24.96% |
| 2005 Q2 | -1.38 Million CAD | -18.42% |
| 2005 Q3 | -1.31 Million CAD | 5.08% |
| 2005 Q4 | -2.22 Million CAD | -69.18% |
| 2005 FY | -6.1 Million CAD | -52.94% |
| 2004 Q2 | -996.33 Thousand CAD | -7.66% |
| 2004 Q4 | -938.03 Thousand CAD | 17.2% |
| 2004 FY | -3.99 Million CAD | 13.5% |
| 2004 Q1 | -925.45 Thousand CAD | -28.99% |
| 2004 Q3 | -1.13 Million CAD | -13.7% |
| 2003 Q2 | -1.14 Million CAD | -8.66% |
| 2003 Q4 | -717.48 Thousand CAD | 57.72% |
| 2003 Q3 | -1.69 Million CAD | -48.05% |
| 2003 FY | -4.61 Million CAD | 18.42% |
| 2003 Q1 | -1.05 Million CAD | 57.13% |
| 2002 Q2 | -923.08 Thousand CAD | 21.78% |
| 2002 Q1 | -1.18 Million CAD | 0.0% |
| 2002 FY | -5.65 Million CAD | 21.38% |
| 2002 Q3 | -1.09 Million CAD | -18.51% |
| 2002 Q4 | -2.46 Million CAD | -124.97% |
| 2001 FY | -7.19 Million CAD | -148.39% |
| 2000 FY | -2.89 Million CAD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Bioxytran, Inc. | -4.28 Million USD | 37.485% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 96.431% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -878.653% |
| SQZ Biotechnologies Company | -79.46 Million USD | 96.633% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | 7.493% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 105.05% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 104.108% |
| Propanc Biopharma, Inc. | -1.82 Million USD | -46.972% |
| Marizyme, Inc. | -65.34 Million USD | 95.905% |
| Genus plc | 7.9 Million USD | 133.869% |
| Pharming Group N.V. | -10.54 Million USD | 74.634% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | -23.313% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | 27.884% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 69.746% |
| ContraFect Corporation | -65.15 Million USD | 95.893% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | -54.89% |
| IMV Inc. | -36.48 Million USD | 92.667% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | 66.802% |
| ONE Bio Corp. | 8.67 Million USD | 130.838% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 94.824% |
| Mesoblast Limited | -87.95 Million USD | 96.958% |
| MultiCell Technologies, Inc. | -380.07 USD | -703890.844% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | 28.324% |
| Genscript Biotech Corporation | -95.47 Million USD | 97.198% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -323.091% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | -12.382% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | 59.312% |
| Biomind Labs Inc. | -1.21 Million USD | -120.342% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | 13.738% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | 66.144% |
| Skye Bioscience, Inc. | -37.64 Million USD | 92.892% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | -37.266% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 75.434% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -17766.306% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | 45.239% |
| Arch Therapeutics, Inc. | -6.98 Million USD | 61.682% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 83.142% |
| Accustem Sciences Inc. | -3.74 Million USD | 28.581% |
| EV Biologics, Inc. | -1.26 Million USD | -111.158% |
| Q BioMed Inc. | -2.05 Million USD | -30.387% |
| GB Sciences, Inc. | -1.36 Million USD | -96.497% |
| Alpha Cognition Inc. | -13.77 Million USD | 80.573% |
| CSL Limited | 2.64 Billion USD | 100.101% |
| Agentix Corp. | -1.37 Million USD | -94.705% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 95.52% |
| Enzolytics Inc. | -2.17 Million USD | -22.915% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Resverlogix Corp. | -3.61 Million USD | 25.882% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | 15.633% |
| MetaStat, Inc. | - USD | Infinity% |
| Curative Biotechnology, Inc. | -5.81 Million USD | 54.005% |
| argenx SE | -295.05 Million USD | 99.093% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 95.726% |
| HST Global, Inc. | -146.21 Thousand USD | -1730.01% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 2830.263% |
| Wesana Health Holdings Inc. | -1.75 Million USD | -52.479% |
| Halberd Corporation | -79.67 Thousand USD | -3258.173% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 138.64% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | 11.582% |
| Zenith Capital Corp. | -10.59 Million USD | 74.748% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | 32.654% |
| GeneThera, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | 35.463% |
| AVAX Technologies, Inc. | -6.41 Million USD | 58.282% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -4326.921% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -33.442% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -11412.168% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Adynxx, Inc. | - USD | Infinity% |
| NovAccess Global Inc. | -4.76 Million USD | 43.897% |
| Helix BioMedix, Inc. | -1.05 Million USD | -153.363% |
| Capstone Therapeutics Corp. | -3.81 Million USD | 29.938% |
| Kadimastem Ltd | -3.3 Million USD | 19.101% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| BioStem Technologies, Inc. | -8.48 Million USD | 68.459% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -506.218% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -100.359% |
| LadRx Corporation | 400.44 Thousand USD | 768.174% |
| Cell Source, Inc. | -5.32 Million USD | 49.717% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -543.994% |
| Regen BioPharma, Inc. | 1.02 Million USD | 361.42% |
| Regen BioPharma, Inc. | 1.02 Million USD | 361.42% |
| Affymax, Inc. | -14.42 Million USD | 81.45% |
| Mobile Lads Corp. | -2.26 Million USD | -18.22% |
| Itoco Inc. | -1.86 Million USD | -43.16% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | 39.772% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | -60.315% |
| International Stem Cell Corporation | -131 Thousand USD | -1942.487% |
| CytoDyn Inc. | -49.84 Million USD | 94.632% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -3285.495% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -1072.881% |
| Qrons Inc. | -789.34 Thousand USD | -238.971% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -184.182% |
| SYBLEU INC | -180.3 Thousand USD | -1383.97% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -2.08 Million USD | -28.164% |
| Rebus Holdings, Inc. | -1.02 Million USD | -162.319% |
| GlobeImmune, Inc. | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | -65.908% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -4830.089% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | -5.747% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 94.434% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | -26.568% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -242.643% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | 15.541% |
| Neutra Corp. | -233.46 Thousand USD | -1046.064% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 86.814% |
| PureTech Health plc | -65.69 Million USD | 95.927% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 87.418% |
| IXICO plc | -1.17 Million USD | -127.136% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 73.047% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 95.316% |
| CSL Limited | 2.64 Billion USD | 100.101% |
| Cellectis S.A. | -103.17 Million USD | 97.407% |